Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus

Li, Jian; Luo, Minghua; Ou, Huiting; Liu, Xiaoling; Kang, Xueling; Yin, Weihua

doi:10.7150/jca.36125

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(26):6635-6648. doi:10.7150/jca.36125 This issue Cite

Research Paper

Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus

Jian Li^1,2, Minghua Luo¹, Huiting Ou³, Xiaoling Liu⁴, Xueling Kang⁵, Weihua Yin^1✉

1. Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
2. State Key Laboratory of Chemical Oncogenomics, Peking University Shenzhen Graduate School, Shenzhen, Guangdong Province, 518055, China.
3. Department of Endocrinology, Shenzhen Second People's Hospital, Guangdong Province, 518035, China.
4. Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.
5. Department of Oncology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, 518036, China.

Citation:

Li J, Luo M, Ou H, Liu X, Kang X, Yin W. Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus. J Cancer 2019; 10(26):6635-6648. doi:10.7150/jca.36125. https://www.jcancer.org/v10p6635.htm

Other styles

Abstract

Although the majority of papillary thyroid cancers (PTC) are indolent, a subset of PTCs behaves aggressively due to extensive invasion and distant metastasis. Integrin β4, a member of the integrin family, has been shown to enhance the progression in some malignancies; however, its role in PTC remains unclear. Here, we demonstrated that β4 overexpression was associated with extrathyroid extension, lymph node metastasis, high TNM stage, and poor overall survival based on The Cancer Genome Atlas cohort. Immunohistochemistry showed that β4 expression was significantly upregulated in the tumors with infiltrating growth pattern, as well as those with positive lymphovascular invasion. Moreover, β4 was invariably overexpressed in the lymphovascular tumor thrombi, which has not been reported before. After shRNA-induced knockdown of β4 in vitro, the migration, invasion and scratch repair ability of the tumor cells were significantly reduced. Furthermore, β4 reduction decreased anchorage-independent growth and increased anoikis. The bioinformatics analysis revealed that approximately 70 pathways were significantly dysregulated in the high β4 expression group. The MAPK pathway and propanoate metabolism were located in the network center of those pathways. Taken together, our results suggest that β4 could promote the tumor's aggressiveness by enhancing invasion and antagonizing anoikis. The upregulated expression of β4 in the tumor thrombi is intrinsically linked to its role in strengthening the anoikis resistance.

Keywords: integrin β4, papillary thyroid carcinoma, anoikis, lymphovascular tumor thrombus

Citation styles

APA

Li, J., Luo, M., Ou, H., Liu, X., Kang, X., Yin, W. (2019). Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus. Journal of Cancer, 10(26), 6635-6648. https://doi.org/10.7150/jca.36125.

ACS

Li, J.; Luo, M.; Ou, H.; Liu, X.; Kang, X.; Yin, W. Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus. J. Cancer 2019, 10 (26), 6635-6648. DOI: 10.7150/jca.36125.

NLM

CSE

Li J, Luo M, Ou H, Liu X, Kang X, Yin W. 2019. Integrin β4 promotes invasion and anoikis resistance of papillary thyroid carcinoma and is consistently overexpressed in lymphovascular tumor thrombus. J Cancer. 10(26):6635-6648.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.